Prostate Cancer Foundation VL

Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery

Details
Bruce Montgomery shares an update on the PCF - VA research Initiative on precision oncology in prostate cancer. Prostate Cancer Foundation has provided a $50 million dollar contribution to this VA specific prostate cancer effort. Bruce and Chuck Ryan discuss the developments to date and the future plans. Biographies: Bruce Montgomery, MD Board-certified oncologist, clinical director of Genitourina...

The Next Big Thing in Prostate Cancer: Neal Shore, Alicia Morgans, and Charles Ryan

Details
In this conversation, Neal Shore, Alicia Morgans and Chuck Ryan discuss their views on what the next “big thing” is in prostate cancer and exciting new developments in 2019. These advancements include a renewed look at the patient’s experience and point of view to integrate into treatment decision making. The group sees continued research in race and genetic disparities and how these factors effec...

Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases - Oliver Sartor

Details
Biographies: A. Oliver Sartor, MD, is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments. Neal Shore, MD, FACS Board Certified Urologist, Medical Director of the Carolina Urologic Research Center, Atlantic Urology...

Improving Natural Killer Cell Immunotherapy for Cancer - Martin Felices

Details
Martin Felices discusses a unique approach to using natural killer (NK) cells to target a variety of cancers. NK cells seek out abnormal cells while also producing inflammatory cytokines that induce the adaptive immune response. There is a known role of NK cells in hematologic malignancies whereas in tumor micro environments the NK cells display characteristics of exhaustion and lack of maturation...

Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor

Details
Biographies: A. Oliver Sartor, MD, is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments. Neal Shore, MD, FACS Board Certified Urologist, Medical Director of the Carolina Urologic Research Center, Atlantic Urology...

Role of PARP Inhibitors in Prostate Cancer - Evan Yu

Details
Biographies: Evan Yu, MD a medical oncologist and Professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, UW Medicine Neal Shore, MD, FACS is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks:...

Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais

Details
Biographies: Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology UCLA Nuclear Medicine Department Los Angeles, CA Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology and Transplantation. Related Con...

Integrating Social Media as an Effective Teaching Tool for Patients - Stacy Loeb

Details
Stacy Loeb discusses with Alicia Morgans her successful implementation of a Twitter-based prostate cancer journal club for patients that was implemented in 2017, under #prostatejc. They also discuss the necessity to vet the quality of information available to consumers. Stacy refers to a content analysis of YouTube videos related to prostate cancer, published in 2017 in the American Journal of Men...

25 Years of Impact: The Prostate Cancer Foundation - Howard Soule

Details
Howard Soule, Executive Vice President & Chief Science Officer of the Prostate Cancer Foundation highlights PCFs 25th-year milestone in shaping the direction of prostate cancer research in this conversation with Alicia Morgans. Howard shares how the foundation was started, how it is impacting prostate cancer research and the future directions of the foundations impactful work. Howard shares his pe...

Targeting Glutamine Metabolism Pathways for the Treatment of Prostate Cancer - Richard Lee

Details
Richard Lee, a 2017 PCF Challenge Award recipient, discusses his research on the metabolics of prostate cancer. The upcoming Phase 1 research in men with CRPC is centered around inhibiting the glutaminase pathway in combination with a PARP inhibitor. The rationale for targeting the glutaminase pathway stems from the fact that cancer cells deplete glucose as a carbon source, a necessary element for...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe